Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Parallel group, Wait-list design, with treatment delayed for 3 months. Participants will be randomized on a 1:1 ratio with 500 participants per group in Australia. Group 1: Wait-list control. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment. Group 2: Initial treatment. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
Description: The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal in the initial treatment and wait-list control groups assessed at the end of 3 months.
Measure: Acute Respiratory Infection necessitating workforce removal Time: 3 monthsDescription: The time to the first ARI necessitating workforce removal in the initial treatment and wait-list control groups.
Measure: Time to ARI necessitating workforce removal. Time: 12 monthsDescription: The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal in the initial treatment and wait-list control groups assessed at the end of 6 and 12 months
Measure: The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal Time: 12 monthsDescription: The proportion of HCW in the initial treatment and wait-list control group with Cov infection documented by molecular techniques of seroconversion
Measure: The proportion of HCW with documented Cov infection. Time: 12 monthsDescription: The time to the first LRI necessitating workforce removal in the initial treatment and wait-list control groups.
Measure: Time to Lower respiratory infection (LRI) necessitating workforce removal. Time: 12 monthsDescription: The proportion of Health Care Workers contracting LRI necessitating workforce removal in the initial treatment and wait-list control groups assessed at the end of 3, 6 and 12 months
Measure: The proportion of Health Care Workers contracting a LRI necessitating workforce removal Time: 12 monthsDescription: The proportion of HCW in the initial treatment and wait-list control group with LRI due to Cov infection documented by molecular techniques of seroconversion
Measure: The proportion of HCW with documented Cov LRI. Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports